Member Info for KingHomerJ

Successful completion and positive data from the PREDICT-ONC trial would significantly impact the value of the dosing tool by providing the necessary clinical validation for its effectiveness in a real-world setting.

Clinical and Commercial Validation: The trial aims to prove that the software's predictive capabilities are accurate and effective in improving patient outcomes (reducing neutropenia risk and side effects) and optimizing treatment costs.

Enhanced Marketability: Positive trial data is essential for regulatory approval as a Software as a Medical Device (SaMD) and for integration into clinical workflows and Electronic Health Record (EHR) platforms used by hospitals and oncology centers. This validation would make the tool a much more attractive asset to potential buyers or partners, such as a large CRO.

Revenue Model Shift: Success could enable a shift from a project/consultancy-based revenue model to a highly scalable, recurring subscription or per-patient licensing model for the software, drastically increasing its long-term commercial value.

Strategic Acquisition Appeal: A validated, ready-to-deploy software asset with proven clinical efficacy would be a prime target for acquisition by a major CRO or pharmaceutical company, potentially commanding a valuation in the millions, far exceeding its current nominal value as a mere "project".

Addressing Unmet Need: Chemotherapy-induced neutropenia is a common and serious side effect, and G-CSF is an expensive drug. A tool that optimizes its use addresses a clear unmet clinical need and a major healthcare cost driver, making it a highly valuable proposition.

In essence, the PREDICT-ONC trial is designed to turn the dosing tool from a promising piece of technology into a validated, market-ready product, which is the key to unlocking its substantial commercial value.

Market Data Desk - GlobaData

Share you know my point is true and valid about the dosing tool and always I’ve stated this is the companies key IP when approved…..

And in my view when this comes to its end point this will be bought and the company as there is serious value in it……

For the consultancy- they company is doing better than it has over the past 5 years - they need more contract its simple as that…..but again its very very close to break even.

I wouldn’t be surprised if there is more positive news next week….lets see

People who are waiting for an oil company to strike oil don't value the company according to it's revenue, they value it on future profitability, so you've just proved my point.

Not sure how i have proved your point as surely its exactly the same thing people see future profitability in the IP of the dosing software which is currently on its 2nd trial with the NHS, has beyond blood diagnostics as a partner as well as Dosemrx and has been given 3 government grants for its development....

Surely this is why people are investing based on the potential of the profitability???? on a MC of 800k

So you are saying the precision dosing tool and IP under development and in trials is worthless….

Clearly all the funding, and partnerships linked to it don’t think so.

Is an oil company worth £20/40/100million before they strike oil then either FO / get TO / become a producer?????

The company has enough cash until the august 2026 as per the company accounts and you know this....This doesn't take into account any contracts won since that date....

He worked for the company prior to being announced as CEO?????

Do your research….

The CEO has been with the company for 4 years?

People leave roles for numerous reasons, mainly personal......

Just because someone leave a role.....in fact any role at any company doesn't mean the company is underperforming and doesn't mean all of the current progress isnt true and fact.

People leave roles for numerous reason.....

Oh and the CEO is standing down in 6 Months time???

VikR,

Are you aware that PYC has precision dosing tool application currently in Trials with Beyond Blood Diagnostics and the NHS.....and a Heads of Terms agreement with DosemeRX.....

The Trials is due to complete in the New Year....This tool has taken years to develop and is coming to its commercialisation point....?

Trout….there was no trades yesterday….

It’s on fire 🔥 today….

Trout……

Sorry to say… you or wrong

Serious question tbh….. are people really buying or selling based on this platform ???

I really don’t care either way tbh but surely it’s not a thing?????

People I see are arguing over a buy or a sell or the mid price.

All I know is I’ve purchased over a million shares in 2 weeks which has been shown on LSE as a sell ???

I’d suggest anyone with any opinions contacts dr Pete the CEO directly and I’m positive they will be reassured

Frankly - if anyone follows / exits a share a share based on comments positive / negative on a share forum shouldn’t be investing.

If people don’t like a share I question the motive why they would spend hours posting negativity on something they are not invested.

If people do however find potential value then they should research all the fundamentals.

It’s really that simple….

This he said / she said / it said is school playground behaviours

We are delighted that our publication from earlier this year has been recognised by the Pharmacometrics Approach Group in Japan community and awarded the inaugural 'Best Paper Award' at the recent 41st Pharmacometrics workshop held in Kyoto.

Together with our coauthors at Astellas Pharma, we described a multiple-model-informed approach for optimising dosing regimens for an oncolytic virus in combination with the anti-PD1 antibody pembrolizumab, applying the Physiomics plc proprietary Virtual Tumour platform and a parallel QSP model developed by the Astellas team.

The findings demonstrated that for optimal efficacy, both treatments should be administered on the same day, with the oncolytic virus dosed ahead of pembrolizumab administration.

🗨️ The work is an excellent example of the use of MIDD approaches to explore numerous dosing scenarios ahead of clinical trials and aligns with the guidance of Project Optimus. Read the full paper

Super …..the company has no debt and never has…..

So not sure what you are referring to?

Be Just voting results as per.

Just to point out one thing….for a low liquidity share….there is a lot of posts and likes (from the same person btw)

That’s says enough really…..

It’s all noise….

If you do your research, understand the companies position, understand its potential, understand the space it’s working in, understand its value vs peers, understand the probability of success, understand the company is in it strongest position in years.

Everything anyone says is pretty irrelevant

I mean anything is always possible....

id of thought that if anything they would buy / gain an interest in the dosing tool...

(This maybe already in place to some extent)

DoseMe, a global leader in model-informed precision dosing (MIPD) software and a portfolio company of Fairlong Capital, today announced the acquisition of Firstline, a leading clinical decision support platform utilized worldwide. Firstline enables clinicians to rapidly access local, evidence-based infectious disease treatment guidance, susceptibility patterns, and antimicrobial stewardship (AMS) resources. The combination of DoseMe and Firstline creates a single, connected experience from therapy selection through personalized dosing, giving clinicians a faster path to optimal care.

“Firstline is the perfect complement to DoseMe with proven value that provides impact on patient outcomes, hospital ecology, and combating antimicrobial resistance,” said Paul Edwards, CEO of DoseMe. “Together, we support AMS initiatives and speed up optimized patient care decisions by helping clinicians access local stewardship protocols and translate them directly into personalized precision dosing.”

Antibiotic-resistant infections drive a significant and rapidly rising burden for providers. These infections cost the U.S. healthcare system between $21 billion and $34 billion annually, driving more than 8 million excess hospital days. Health systems need integrated solutions, turning stewardship policy into actionable intelligence at the point of care.

“We’re immensely proud to have built Firstline into an organization delivering clinical guidance globally to hospitals, governments and the World Health Organization”, said Dr. Michael Long, co-founder and Chief Clinical Officer of Firstline. “We’re excited to see Firstline continue to flourish as part of the larger DoseMe organization.”

“The combination of DoseMe and Firstline advances the mission to address the full patient care continuum of personalized medicine. We look forward to the consolidated business’ continued growth, but most importantly to the profound impact this combination will have on the customer’s ability to improve patient care,” said David Neiman, Managing Partner at Fairlong Capital.

There are many different rules and regs globally.

This is about the MHRA and US FDA  - FDA being a bit more relaxed than MHRA in terms of approvals (probably hence the link up with dosemerx)

This is about MHRA and FDA alining which will speed approvals up, reduce time for approvals significantly and also reduce costs significantly……allowing products / software to be brought to market faster.

Could this benefit PYC with the dosing tool…..probably